DARPin Targeted Magnetic Hyperthermic Therapy for
Glioblastoma
FP7
 
   Partner:
nanoPET Pharma GmbH

Project Leader
Dr. Nicole Gehrke

Group Members
Dr. Andreas Briel
Dr. Anne Kirchherr
Dr. Danielle Franke
Dr. Alexander Kraupner
Dr. Sabine Seedorff
Semray Yasar
Anna Steinle
Stefanie Runge
Bianca Grunert




Selected publications


Lohrke J, Briel A, Mäder K Characterization of superparamagnetic iron oxide nanoparticles by asymmetrical flow-field-flow-fractionation. Nanomed 2008; 3(4):437-52

Linker RA, Reinhardt M, Bendszus M, et al. In vivo molecular imaging of adhesion molecules in experimental autoimmune encephalomyelitis (EAE). J. of Autoimmunity 2005; 25(3):199-205

Reinhardt M, Hauff P, Linker RA, et al. Ultrasound derived imaging and quantification of cell adhesion molecules in experimental autoimmune encephalomyelitis (EAE) by Sensitive Particle Acoustic Quantification (SPAQ). Neuroimage 2005;27:267–78

Gehrke N, Briel A, Ludwig F, et al. New Perspectives for MPI: A Toolbox for Tracer Research. T. M. Buzug and J. Borgert (Eds.): Magnetic Particle Imaging 2012, SPPHY 140, pp. 99-103


 
General introduction to nanoPET Pharma GmbH

As a technology and service provider to the biopharmaceutical industry, nanoPET is specialized in the R&D and production of innovative agents for diagnostic imaging. Our customers benefit from the long-standing industry expertise our team has attained in the pharmaceutical development of clinical contrast agents. Nanotechnology is a key element of our business allowing us to offer you materials with unique features.

We offer our comprehensive Viscover™ portfolio of contrast agents/tracers for pre-clinical animal imaging for use in all imaging modalities: Magnetic Resonance Imaging (MRI), Computed Tomography (CT), Ultrasound (US), Optical Imaging (OI), SPECT (Single Photon Emission Computed Tomography) & PET (Positron Emission Tomography). Using innovative nanotechnologies most of our agents are far ahead of the human clinical routine, yet we provide the clinical standard agents as well.
NanoPET also provides custom solutions including consulting, imaging agent development, pharmaceutical formulation as well as study planning and analysis. Our specialties are organ- and molecular-targeted agents for all modalities. In the field of pre-clinical animal imaging and nanomaterials, we offer a variety of collaboration opportunities that range from pilot studies to long-term R&D partnerships. For more information visit our portfolio website: www.viscover.com.


Role of nanoPET within the “Dartrix Consortium”

As a partner within the DARTRIX project, nanoPET is responsible for the generation, formulation and in vitro evaluation of the DARTRIX particles. This includes the establishment of conjugation methods of DARPins to ferucarbotran. Furthermore, the particles will be optimized with respect to their RES uptake and enhance their heating properties. nanoPET will employ physic-chemical analytical methods and establish various in vitro cell assays for the comprehensive characterization of the DARTRIX particles.




   Copyright © 2012-15 - Dartrix